Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 3094 | 2.32 |
09:38 ET | 200 | 2.31 |
09:39 ET | 400 | 2.32 |
09:41 ET | 300 | 2.33 |
09:43 ET | 100 | 2.34 |
09:45 ET | 1085 | 2.33 |
09:50 ET | 500 | 2.33 |
09:52 ET | 332 | 2.33 |
09:54 ET | 100 | 2.32 |
09:56 ET | 1100 | 2.33 |
09:57 ET | 800 | 2.33 |
09:59 ET | 200 | 2.33 |
10:01 ET | 100 | 2.31 |
10:06 ET | 3133 | 2.31 |
10:08 ET | 1202 | 2.3 |
10:10 ET | 1050 | 2.31 |
10:14 ET | 300 | 2.31 |
10:17 ET | 200 | 2.3 |
10:19 ET | 1603 | 2.3 |
10:21 ET | 200 | 2.29 |
10:26 ET | 1400 | 2.3 |
10:30 ET | 200 | 2.3 |
10:32 ET | 399 | 2.301 |
10:33 ET | 499 | 2.295 |
10:37 ET | 100 | 2.29 |
10:42 ET | 1662 | 2.29 |
10:46 ET | 150 | 2.28 |
10:50 ET | 100 | 2.26 |
10:53 ET | 200 | 2.27 |
10:57 ET | 200 | 2.26 |
11:00 ET | 200 | 2.28 |
11:02 ET | 300 | 2.27 |
11:06 ET | 200 | 2.26 |
11:09 ET | 200 | 2.26 |
11:11 ET | 100 | 2.265 |
11:13 ET | 10112 | 2.2793 |
11:18 ET | 200 | 2.29 |
11:20 ET | 1105 | 2.29 |
11:26 ET | 200 | 2.28 |
11:27 ET | 700 | 2.29 |
11:29 ET | 200 | 2.28 |
11:33 ET | 200 | 2.28 |
11:36 ET | 100 | 2.3 |
11:38 ET | 200 | 2.28 |
11:40 ET | 105 | 2.29 |
11:42 ET | 200 | 2.28 |
11:44 ET | 100 | 2.3 |
11:45 ET | 200 | 2.28 |
11:47 ET | 2600 | 2.3 |
11:49 ET | 100 | 2.28 |
11:54 ET | 200 | 2.28 |
11:58 ET | 500 | 2.28 |
12:00 ET | 100 | 2.285 |
12:02 ET | 743 | 2.28 |
12:05 ET | 100 | 2.28 |
12:09 ET | 100 | 2.285 |
12:14 ET | 200 | 2.27 |
12:18 ET | 380 | 2.27 |
12:21 ET | 200 | 2.27 |
12:23 ET | 300 | 2.27 |
12:25 ET | 200 | 2.27 |
12:30 ET | 200 | 2.27 |
12:34 ET | 100 | 2.27 |
12:38 ET | 4004 | 2.2605 |
12:41 ET | 200 | 2.26 |
12:45 ET | 200 | 2.26 |
12:50 ET | 13573 | 2.26 |
12:54 ET | 519 | 2.26 |
12:56 ET | 400 | 2.26 |
12:57 ET | 100 | 2.25 |
01:01 ET | 424 | 2.25 |
01:06 ET | 1300 | 2.25 |
01:10 ET | 200 | 2.25 |
01:14 ET | 300 | 2.25 |
01:17 ET | 300 | 2.25 |
01:21 ET | 200 | 2.25 |
01:26 ET | 500 | 2.26 |
01:28 ET | 100 | 2.25 |
01:30 ET | 200 | 2.25 |
01:33 ET | 200 | 2.25 |
01:37 ET | 200 | 2.25 |
01:42 ET | 300 | 2.25 |
01:46 ET | 3193 | 2.25 |
01:50 ET | 279 | 2.24 |
01:51 ET | 1000 | 2.235 |
01:53 ET | 6614 | 2.245 |
01:57 ET | 974 | 2.25 |
02:02 ET | 300 | 2.255 |
02:04 ET | 2940 | 2.255 |
02:06 ET | 100 | 2.25 |
02:08 ET | 300 | 2.255 |
02:09 ET | 300 | 2.25 |
02:11 ET | 1379 | 2.265 |
02:13 ET | 400 | 2.26 |
02:15 ET | 300 | 2.26 |
02:18 ET | 200 | 2.25 |
02:20 ET | 200 | 2.26 |
02:22 ET | 318 | 2.25 |
02:26 ET | 200 | 2.25 |
02:29 ET | 300 | 2.25 |
02:31 ET | 200 | 2.25 |
02:33 ET | 100 | 2.25 |
02:38 ET | 1170 | 2.26 |
02:40 ET | 735 | 2.27 |
02:42 ET | 400 | 2.27 |
02:44 ET | 435 | 2.2589 |
02:45 ET | 635 | 2.26 |
02:47 ET | 200 | 2.25 |
02:49 ET | 200 | 2.25 |
02:54 ET | 1030 | 2.25 |
02:58 ET | 200 | 2.25 |
03:02 ET | 835 | 2.26 |
03:05 ET | 200 | 2.25 |
03:07 ET | 635 | 2.26 |
03:09 ET | 300 | 2.25 |
03:12 ET | 970 | 2.26 |
03:14 ET | 635 | 2.26 |
03:16 ET | 1505 | 2.26 |
03:18 ET | 7115 | 2.23 |
03:20 ET | 250 | 2.24 |
03:21 ET | 1000 | 2.235 |
03:25 ET | 300 | 2.23 |
03:27 ET | 900 | 2.235 |
03:30 ET | 3510 | 2.245 |
03:32 ET | 2200 | 2.245 |
03:34 ET | 300 | 2.245 |
03:36 ET | 100 | 2.245 |
03:38 ET | 200 | 2.24 |
03:41 ET | 2002 | 2.24 |
03:45 ET | 753 | 2.24 |
03:48 ET | 4456 | 2.24 |
03:50 ET | 498 | 2.23 |
03:52 ET | 100 | 2.24 |
03:54 ET | 1182 | 2.24 |
03:56 ET | 400 | 2.23 |
03:57 ET | 5269 | 2.24 |
03:59 ET | 800 | 2.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 117.7M | -0.5x | --- |
Tevogen Bio Holdings Inc | 118.1M | -1,653.5x | --- |
Nuvectis Pharma Inc | 119.5M | -4.6x | --- |
Regulus Therapeutics Inc | 115.2M | -1.2x | --- |
Compass Therapeutics Inc. | 121.1M | -2.5x | --- |
Corvus Pharmaceuticals Inc | 111.3M | -3.5x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $117.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.37 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.